Amendment to Offer Letter Between Ensysce Biosciences Inc. and David Humphrey (February 23, 2021)
Ensysce Biosciences Inc. and David Humphrey have agreed to amend the equity award terms in Mr. Humphrey's February 11, 2021 offer letter. Instead of receiving a stock option grant equal to 1.0% of the merged company's equity incentive plan, Mr. Humphrey will now receive a grant of 275,000 shares under the plan, once the contemplated merger closes. All other terms of the original offer letter remain unchanged.
Exhibit 10.27
February 23, 2021
David Humphrey
Via email:
| Re: | Offer Letter February 11, 2021 Amendment |
Dear Dave:
This letter is to amend the Equity Award language of the fully executed February 11, 2021 Offer Letter from “Once the contemplated merger transaction closes you will be provided a stock option grant in a quantity representing 1.0% of the merged Company’s newly formed Equity Incentive Plan (the “Plan”). To “Once the contemplated merger transaction closes you will be provided a stock option grant of 275,000 shares of the merged Company’s newly formed Equity Incentive Plan (the “Plan”).
All other language in the February 11, 2021 Offer letter will remain the same.
Sincerely,
| /s/ Lynn Kirkpatrick | |
| Lynn Kirkpatrick | |
| Chief Executive Officer |
Acknowledged:
| /s/ David Humphrey | |
| Dave Humphrey |
02/23/2021
Date
Ensysce Biosciences Inc.
7946 Ivanhoe Ave. Ste 201 - La Jolla, CA – 92037 www.ensysce.com
